| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Robert B Catell is Director at BRTX, with reported holdings spanning 2 companies. Robert B Catell's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $122K at current prices.
Robert B Catell's largest disclosed position is in BRTX as Director, worth about $120K. Net of sales, the BRTX filings show accumulation of 55,000 shares.
Robert B Catell has 23 Form 4 filings on record from February 2016 to March 2026, across 2 companies: Director at BNB Plus (BNBX), 2016–2026; Director at BioRestorative Therapies (BRTX), 2016–2019.
The 35 reported transactions were 20 option or other derivative awards, 6 open-market purchases, 4 stock awards and 4 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $214K and no sales.
The largest open-market purchase was 37,500 shares of BRTX at an average $4.00 on March 1, 2016, about $150K.